Sorin Group received the European CE Mark approval for the Mitroflow Aortic Pericardial Heart Valve with PRT.
The Phospholipid Reduction Treatment (PRT) of the valve is intended to reduce the calcification of the device and hopefully make it durable as the years wear on.
From the announcement:
Research has demonstrated that phospholipids play a key role in the calcification process of biosprotheses.
PRT has been shown to decrease phospholipid content in the pericardial tissue, which leads to a reduction of up to 99% of calcium uptake in the treated pericardial tissue.
The addition of PRT to the Mitroflow bioprosthesis will help mitigate potential calcification and possibly further improve the tissue valve’s clinically proven outstanding durability.